Introduction
Chronic myeloid leukemia (CML) is a lethal hematological malignancy that results from hematopoietic stem cell (HSC) transformation by the BCR-ABL tyrosine kinase. BCR-ABL expression bestows hematopoietic cells with malignant characteristics, including inappropriate proliferation, reduced apoptosis, and genomic instability. Despite the success of BCR-ABL tyrosine kinase inhibitors (TKIs) in inducing remission and prolonging survival, cures remain elusive because primitive leukemia stem cells (LSCs) are retained, even in patients achieving remission (1, 2). Although a small proportion of CML patients achieving prolonged deep responses can maintain remission after TKI discontinuation, the majority of CML patients require indefinite TKI treatment to prevent disease recurrence, with associated risk of noncompliance, toxicity, and financial burden, (3, 4) . Identifying key mechanisms for the persistence of LSCs is critical for the development of effective therapeutic strategies in CML.
BCR-ABL TKIs effectively inhibit tyrosine kinase activity in CML LSCs, indicating that LSC resistance is related to tyrosine kinase-independent mechanisms (2) . We have previously reported that sirtuin 1 (SIRT1), a NAD + dependent deacetylase, is overexpressed in CML LSCs compared with normal HSCs and that it contributes to CML LSC maintenance and TKI resistance (5, 6) . Importantly, SIRT1 also contributes to LSC maintenance and drug resistance in Flt3 -ITD + acute myeloid leukemia (AML), another oncogenic tyrosine kinase-driven malignancy, indicating a broader importance of SIRT1 in diverse leukemias (7, 8) . SIRTs regulate many cellular pathways, including energy metabolism and stress response to tumorigenesis and aging. SIRT1 is a nuclear protein expressed in almost all cell types and involved in the deacetylation of histones, transcription factors, and signaling proteins that regulate many metabolic and stress-response pathways (9, 10) , including PGC-1α (11) , LXR (12) , PPARγ (13) , FOXO (14) , p53 (15) , and KU70. Although the role of SIRT1 in longevity and stress responses indicates a role as a tumor suppressor, SIRT1 can also enhance tumorigenesis, depending on cellular context (5) (6) (7) (8) (16) (17) (18) (19) . Indeed, SIRT1 is overexpressed in several cancer types and can deacetylate and repress the activity of tumor suppressor p53 (15) .
We have previously shown that SIRT1 inhibition using shRNA or a small molecule SIRT1 inhibitor reduces LSC growth and survival and increases the sensitivity of these cells to TKI (5) . Our results indicate that the effects of SIRT1 inhibition were related, at least in part, to increased p53 acetylation and transcriptional activity. However, previous studies evaluating the role of SIRT1 in regulating LSC growth were limited because of possible offtarget effects of SIRT1 inhibitors and short duration of exposure as well as lack of an unbiased evaluation of mechanisms underlying SIRT1 effects. Here, we have used a genetic knockout model of SIRT1 to definitively delineate the role of SIRT1 in regulating leukemic and normal stem cell growth and in selectively promoting leukemic hematopoiesis and mediating TKI resistance. These studies reveal a previously unrecognized role for SIRT1 in mediating altered mitochondrial metabolism in CML LSCs in a BCR-ABL kinase-independent manner.
Chronic myeloid leukemia (CML) results from hematopoietic stem cell transformation by the BCR-ABL kinase. Despite the success of BCR-ABL tyrosine kinase inhibitors (TKIs) in treating CML patients, leukemia stem cells (LSCs) resist elimination and persist as a major barrier to cure. Previous studies suggest that overexpression of the sirtuin 1 (SIRT1) deacetylase may contribute to LSC maintenance in CML. Here, by genetically deleting SIRT1 in transgenic CML mice, we definitively demonstrated an important role for SIRT1 in leukemia development. We identified a previously unrecognized role for SIRT1 in mediating increased mitochondrial oxidative phosphorylation in CML LSCs. We showed that mitochondrial alterations were kinase independent and that TKI treatment enhanced inhibition of CML hematopoiesis in SIRT1-deleted mice. We further showed that the SIRT1 substrate PGC-1α contributed to increased oxidative phosphorylation and TKI resistance in CML LSCs. These results reveal an important role for SIRT1 and downstream signaling mechanisms in altered mitochondrial respiration in CML LSCs.
SIRT1 regulates metabolism and leukemogenic potential in CML stem cells (P = 0.01) ( Figure 1F ) and multipotent progenitors (MPPs) (LSK, Flt3 -CD150 -CD48 + ) (P = 0.03) ( Figure 1G ) were increased in the BM of SIRT1-deleted mice compared with those in control mice. BM committed progenitor populations, granulocyte-macrophage compared with controls ( Figure 1C ). No significant difference in BM cellularity ( Figure 1D) 2) were transplanted into irradiated (800 cGy) CD45.1 congenic recipients (2 × 10 6 cells/mouse). Cre-mediated deletion of SIRT1 was induced by pIpC injection starting at 4 weeks after transplant, followed by tetracycline withdrawal to induce BCR-ABL expression. Mice were followed for CML and SIRT1 development and analyzed for BM and spleen stem/progenitors (shown in Figure 3 ). (B-D) Peripheral blood parameters were evaluated over time after SIRT1 deletion. Results for WBCs (B), neutrophils (C), and Gr1 (E-I) Effect of SIRT1 deletion on spleen and BM parameters at 8 weeks, including spleen size (E), spleen weight (F), spleen cellularity (G), BM cellularity (H), and frequencies of CD45.2 donor cells, B cells, and myeloid cells by flow cytometry in BM (I) (n = 6 each). Error bars represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001, t test. fl/fl mice compared with Cre controls. Error bars represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001, t test, except Kaplan-Meier analysis. Leko et al., showing that SIRT1 deletion did not affect HSC maintenance and long-term reconstitution in adult mice in the steady state (21) , but are in contrast with other studies that show that SIRT1 deletion results in anemia, myeloid expansion, and lymphoid depletion, associated with DNA damage accumulation, gene expression changes associated with aging, and compromised hematopoiesis with increased HSC cycling and exhaustion in response to stress (22) (23) (24) .
SIRT1 deletion impairs leukemia development in CML mice. To study the requirement of SIRT1 for CML development, we used a well-characterized and representative SCL-tTA/BCR-ABL transgenic mouse model of chronic-phase CML (25) (26) (27) . In this model, tetracycline withdrawal leads to BCR-ABL expression in HSCs and development of a CML-like myeloproliferative disorder. SCL-tTA/BCR-ABL mice were crossed with Mx1-Cre SIRT1 To check the effect of SIRT1 deletion on in vivo repopulating ability, LTHSCs purified from BM of mice that received BA-Mx1-Cre SIRT1 fl/fl or control cells were transplanted into secondary recipients ( Figure 3K ). Mice receiving SIRT1-deleted LTHSCs showed significantly reduced WBC counts ( Figure 3L ) and donor cell engraftment ( Figure 3M ). BM donor engraftment was not reduced ( Figure 3N ), but donor LTHSC engraftment in BM was significantly reduced compared with that in controls ( Figure 3O ), whereas other stem/progenitor populations were not affected ( Figure 3 , P-S). These results are consistent with the hypothesis that SIRT1 deletion results in reduced CML LSC regenerative potential.
A cohort of primary BA Mx1-Cre SIRT1 fl/fl and control mice were followed for survival. SIRT1-deleted mice showed significantly increased survival compared with controls ( Figure 3T ). Cre + mice showed significantly reduced percentages and absolute numbers of neutrophils and Gr1 SIRT1 deletion inhibits expression of mitochondrial genes in CML stem/progenitor cells. We performed global gene expression analysis to obtain further insights into the mechanisms by which SIRT1 deletion exerts antileukemic effects in BCR-ABL mice. We performed RNA-Seq on BM LSK stem cells from SIRT1-deleted and control CML mice and identified differentially expressed genes (2× fold-change, P < 0.05, n = 1,063) ( Figure 6A ). Gene Set Enrichment Analysis (GSEA) was performed to identify gene sets enriched in SIRT1-deleted versus control stem cells (32) (http://www.broadinstitute.org/gsea/). Gene sets most positively enriched in SIRT1-deleted stem cells included those related to UV response, HSC signatures, TP53 targets, and WNT and Notch signaling (Supplemental Table 2 ). The most negatively enriched gene sets in SIRT1-deleted CML stem cells included those related to Myc, mitochondria and oxidative phosphorylation, embryonic stem (ES) cells, ribosomes, proteasomes, and tumor invasiveness ( Figure 6B and Supplemental Table 1 ). Indeed, of the top 25 downregulated gene sets, 10 were related to mitochondria and/or oxidative phosphorylation, and widespread and significant inhibition of expression of mitochondrial electron transport chain-related genes was seen in SIRT1-deleted CML stem cells ( Figure 6C ). Results from SIRT1-deleted and control CML LSKs were compared with an analysis of LTHSCs from CML and WT mice using RNASeq. It was notable that mitochondrial and/or oxidative phosphorylation gene sets were among the top enriched gene sets in CML compared with normal LTHSCs ( Figure 6D ). Moreover, there was a significant negative correlation (r 2 = 0.37, P < 0.0001) between the normalized enrichment scores (NES) of gene sets enriched in CML versus normal stem cells and SIRT1-deleted versus control CML stem cells ( Figure 6E ), and 61 of the top 100 positively enriched gene sets in CML stem cells were negatively enriched in SIRT1-deleted CML LSCs (Supplemental Table 3 ). These results suggest that alterations in gene expression programs in CML stem cells are significantly reversed after SIRT1 deletion.
SIRT1 deletion results in reduced mitochondrial respiration in CML stem/progenitor cells. We investigated the effect of SIRT1 deletion on energy metabolism by performing extracellular flux analysis for cellular bioenergetics and glycolysis in c-Kit + stem/ progenitor cells selected from SIRT1-deleted and control CML and normal mice. Comparing CML and normal mice, we found significantly increased ATP-linked respiration, maximal mitochondrial respiration, and mitochondrial reserve capacity ( Figure 7A ), as well as increased maximal glycolysis and glycolytic reserve ( Figure 7B ), in c-Kit + cells from CML mice compared with normal mice, consistent with recent reports that mitochondrial respiration is increased in CML stem cells (33) . Next, comparing Cre + SIRT1-deleted CML mice (BA UBC-Cre-ERT2 SIRT1 f/f ) and control Cre -CML mice, we observed that SIRT1-deleted CML c-Kit + cells demonstrated significant reduced basal and maximal mitochondrial respiration and reduced mitochondrial reserve capacity compared with control CML c-Kit + cells ( Figure 7C ). In contrast, SIRT1-deleted CML c-Kit
+ cells did not demonstrate alteration in extracellular acidification rate (ECAR) parameters, including maximal glycolysis and glycolytic reserve, compared with control CML cells ( Figure 7D ). We observed a significant increase in the proportion of LTHSCs in the G 1 phase, but a decrease in LTHSCs in the G 0 phase after SIRT1 deletion, indicating that SIRT1 deletion leads to loss of quiescence ( Figure 4N) . A reduction in cells in the S-G 2 -M phase was also seen. Loss of quiescence may explain why LTHSC numbers were increased, but their repopulating ability was reduced, following SIRT1 deletion.
TKI treatment leads to additional suppression of CML hematopoiesis in SIRT1-deleted mice. We studied the effect of BCR-ABL TKIs on SIRT1-deleted CML mice. We have previously shown that TKI treatment does not affect SIRT1 expression in CML stem cells (6) . SIRT1-deleted (BA Mx1-Cre SIRT1 fl/fl ) or control CML mice in whom BCR-ABL was induced for 10 weeks were treated with the potent BCR-ABL TKI nilotinib (NIL) (50 mg/ kg/d) or vehicle for 4 weeks. Blood counts were monitored during treatment (Supplemental Figure 6 , A-C) and mice sacrificed and analyzed after 4 weeks of treatment. NIL treatment resulted in marked reduction in spleen size ( Figure 5A ), weight ( Figure 5B), and cellularity ( Figure 5C ) in control mice, and further modest reduction in these parameters was seen with NIL treatment of SIRT1-deleted mice. BM cellularity was increased upon NIL treatment in control mice, but not further increased on NIL treatment in SIRT1-deleted mice ( Figure 5D ). BM myeloid cells were reduced upon NIL treatment in control mice and further reduced in SIRT1-deleted mice ( Figure 5E ). NIL treatment significantly reduced splenic stem and progenitor cells ( 
(E and F) OCR and ECAR in normal Cre
-(n = 8) and normal Cre + SIRT1-deleted (n = 7) c-Kit + cells. Error bars represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001, 2-way ANOVA correcting for multiple comparisons by controlling the FDR using the 2-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli. 3-6 assay replicate assays were performed for each sample. jci.org Volume 129 Number 7 July 2019 
CD38
-cells (n = 3) were exposed to vehicle, NIL (1 μM), TV39OH (5 μM), or combination for 72 hours and plated in methylcellulose progenitor culture. Colonies were enumerated after 14 days. Error bars represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001, ordinary 1-way ANOVA (G-I) or 2-way ANOVA (B-D) correcting for multiple comparisons by controlling the FDR using the 2-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli. 
-cell colony-forming ability, and the combination of NIL and TV39OH led to further reduction in colony-forming capacity ( Figure 8I ). These results show that combined SIRT1 and BCR-ABL kinase inhibition can enhance suppression of human CML stem/progenitor cells.
PGC-1α regulates mitochondrial metabolism and contributes to TKI resistance in CML stem/progenitor cells. SIRT1 can deacetylate and activate the transcriptional coactivator PGC-1α to enhance mitochondrial DNA replication and gene expression and promote mitochondrial activity in response to energy needs (36) . A PGC-1α-related gene set was enriched in stem/progenitor cells from CML compared with normal mice and downregulated in stem/progenitor cells from SIRT1-deleted compared with control CML mice ( Figure 9A ). Extracellular flux analysis of c-Kit + cells isolated from CML mice following treatment with the PGC-1α inhibitor SR-18292 (45 mg/kg i.p.) for 14 days showed reduced OCR ( Figure  9 , B and C) without change in ECAR (Supplemental Figure 8, A and  B) . Although the PGC-1α inhibitor did not significantly affect CML hematopoiesis by itself, combined treatment with the PGC-1α inhibitor and NIL (50 mg/kg oral gavage) significantly reduced peripheral blood counts, donor engraftment, LSK and c-Kit + cells in spleen, and donor LTHSCs in BM compared with NIL alone (Figure 9 , C-K, and Supplemental Figure 8 Figure 8N ). The PGC-1α inhibitor only modestly enhanced apoptosis and reduced colony-forming cell (CFC) potential of CML CD34 +
-cells by itself, but in combination with NIL, significantly increased apoptosis and reduced CFC numbers compared with NIL alone (Figure 9, M and N) . These results support an important role for PGC-1α in enhanced mitochondrial respiration in CML stem/progenitor cells. They also indicate that PGC-1α inhibition does not directly suppress CML hematopoiesis, but inhibits leukemic hematopoiesis in combination with TKI treatment.
Discussion
In this study, we demonstrate that the SIRT1 deacetylase plays an important role in maintaining the regenerative potential of CML LSCs and promoting leukemia development in CML. Our studies provide a conceptual advance and biological insights regarding the activity of SIRT1 and its role in CML LSCs. It has been reported that CML LSCs rely on upregulated mitochondrial oxidative metabolism for survival (33) . However, the underlying mechanisms are not known. Our studies reveal an important role for SIRT1 and the SIRT1 substrate PGC-1α in mediating enhanced mitochondrial oxidative phosphorylation in LSCs. Increased mito-NIL-treated CML mice did not demonstrate significant changes in mitochondrial bioenergetics ( Figure 8 , A and B) or glycolytic parameters (Supplemental Figure 7A ) compared with cells from vehicle-treated mice. These results suggest that increased mitochondrial respiration in murine CML stem/progenitor cells is BCR-ABL kinase independent.
GSEA analysis of reported gene expression data for CD34 +
CD38
-stem cells from CML patients with or without treatment with the TKI imatinib showed that TKI-treated CML stem cells did not demonstrate significant enrichment of mitochondrialor oxidative phosphorylation-related gene sets compared with vehicle-treated controls (not shown) (34) . We studied the effects of SIRT1 inhibition and TKI treatment on mitochondrial energetics in human CML CD34 + stem and progenitor cells. Our previous studies used the SIRT1 inhibitor, Tenovin 30 (TV30), which has recently been shown to have additional autophagy inhibitory effects that could affect mitochondrial mass and function independently of SIRT1. Therefore, for the current studies, we used a congener, Tenovin 39OH (TV39OH), which retains SIRT1 inhibitory effects, but does not have autophagy inhibitory properties (35) . CML BM CD34 + cells were treated with TV39OH (5 μM), the TKI NIL (1 μM), or a combination. SIRT1 inhibition with TV39OH resulted in significant reduction in oxygen consumption rate (OCR) in CML CD34
+ cells compared with vehicle controls ( Figure  8C ), without significantly affecting ECAR ( Figure 8D ), consistent with results obtained with SIRT1 deletion in murine CML stem cells. In contrast, NIL treatment did not affect OCR or ECAR in CML CD34
+ cells compared with vehicle controls. These results indicate that increased mitochondrial respiration in human CML stem/progenitor cells is also kinase independent.
We evaluated the effect of treatment with NIL, TV39OH, or the combination on CML stem/progenitor cell viability and growth. CML CD34 +
-stem/progenitor cells and CD34 + CD38
+ committed progenitors cultured for 72 hours with TV39OH or NIL both showed significant reduction of CML cell proliferation compared with controls, as measured by reduction in + CD38 -cells (n = 3) exposed to vehicle, PGC-1α inhibitor, NIL, or combination for 48 hours and plated in methylcellulose progenitor culture. Error bars represent mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001, ordinary 1-way ANOVA (M and N) , Kruskal-Wallis 1-way ANOVA (C-K), or 2-way ANOVA (B and L), correcting for multiple comparisons by controlling the FDR using the 2-stage linear step-up procedure of Benjamini, Krieger, and Yekutieli. jci.org Volume 129 Number 7 July 2019
to increased AMPK activation and PGC-1α phosphorylation (36, 46) . PGC-1α gene sets were upregulated in CML stem/progenitor cells and markedly downregulated upon SIRT1 deletion. PGC-1α inhibition substantially reduced mitochondrial oxygen consumption, supporting an important role in regulation of mitochondrial metabolism in CML stem/progenitor cells. Interestingly, PGC-1α inhibition did not directly inhibit CML hematopoiesis, suggesting that additional SIRT1-related mechanisms besides regulation of mitochondrial respiration are also involved in promoting CML stem/progenitor cell growth. SIRT1 overexpression is known to lead to p53 deacetylation and inhibition of p53 activity in CP CML LSCs, and effects of SIRT1 inhibition on leukemic hematopoiesis are mediated at least in part to increased p53 acetylation and transcriptional activity (5, 7, 47) . Indeed, p53-related gene signatures were substantially enriched in SIRT1-deleted CML stem cells. In the future, it will be of interest to explore interactions between SIRT1 regulation of metabolism and its regulation of p53 in the effects of SIRT1 inhibition on LSCs. Gene expression and extracellular flux analyses indicate that TKI treatment does not significantly alter mitochondrial oxidative phosphorylation in human or murine CML LSCs, suggesting that altered oxidative phosphorylation in CML LSCs may be TKI independent. This is consistent with previous observations that TKI treatment does not inhibit SIRT1 activity in CML LSCs (5) . TKI treatment increased suppression of leukemic hematopoiesis in SIRT1-deleted mice compared with control CML mice. Similarly, treatment of human CML stem cells with a SIRT1 inhibitor in combination with TKI resulted in substantially greater apoptosis and proliferation inhibition than either agent alone. Interestingly, PGC-1α inhibition resulted in marked suppression of leukemic hematopoiesis in combination with TKI, compared with TKI alone, suggesting that PGC-1α, although not essential for leukemia development, may contribute to maintenance of CML stem/ progenitor cells following TKI treatment. However, our studies suggest that SIRT1 and PGC-1α inhibition, although further suppressing residual CML stem/progenitor cells, may not result in their elimination.
Development of effective approaches for targeting CML LSCs that persist despite TKI treatment without toxicity to normal HSCs has been challenging. In previous studies, SIRT1 inhibition by shRNA or pharmacological means did not affect normal human stem or progenitor cell survival (5) . In our studies, SIRT1 loss from normal HSCs did not inhibit steady-state normal hematopoiesis. However, we cannot rule out a requirement for SIRT1 in HSC maintenance under chronic stress conditions and with chondrial metabolism in LSCs is BCR-ABL kinase independent, and TKI treatment of SIRT1-deleted mice results in further suppression of leukemic hematopoiesis. Identification and targeting of SIRT1-regulated mechanisms responsible for mitochondrial alterations may facilitate selective targeting of mitochondrial abnormalities in CML LSCs.
SIRT1 knockout impaired development of CML in transgenic BCR-ABL mice, as mice showed substantial delays in development of leukocytosis, neutrophilia, splenomegaly, morbidity, and death. SIRT1 deletion also reversed redistribution of CML stem cells from the BM to the spleen, reduced CML LSC quiescence, resulting in fewer quiescent G 0 phase cells and increased G 1 phase cells, and reduced regenerative capacity of LSCs after transplantation. These results definitively demonstrate an important role for SIRT1 in myeloproliferation and extramedullary hematopoiesis that is characteristic of CML. However, the lack of elimination of LSCs in the BM may contribute to delayed development of leukemia in SIRT1-deleted mice.
Quiescent HSCs reside in hypoxic niches in the BM cavity and rely on glycolysis, rather than oxidative phosphorylation, to support ATP production (37, 38). Self-renewing HSCs limit mitochondrial respiration to remain in a quiescent state, but switch to oxidative phosphorylation on activation and differentiation (39) . In contrast to normal HSCs and bulk tumor cells, cancer stem cells show distinct metabolic phenotypes and, depending on cancer type, are variably dependent on oxidative phosphorylation or on glycolysis for growth and maintenance (40) . CML and AML LSCs are reported to upregulate oxidative phosphorylation and be selectively targeted by inhibitors of mitochondrial translation, such as tigecycline (33, 41, 42) . However, previous studies have not addressed the mechanisms of altered mitochondrial metabolism in leukemia versus normal stem cells.
Our results suggest that increased mitochondrial respiration in CML LSCs is tyrosine kinase independent and SIRT1 dependent. SIRT1 is a NAD + -dependent enzyme that is a cellular metabolic sensor with multiple regulatory effects on cellular metabolism (43) . Extracellular flux analysis revealed that increased mitochondrial respiration in CML LSCs is markedly reduced upon SIRT1 deletion. In contrast, SIRT1 deletion did not affect mitochondrial respiration in normal HSCs. These results support an important role for SIRT1 overexpression in mediating enhanced oxidative phosphorylation in LSCs compared with HSCs. SIRT1 can deacetylate and activate the transcriptional coactivator PGC-1α to enhance mitochondrial DNA replication and gene expression and promote mitochondrial biogenesis and activity (44, 45) . SIRT1 can also lead to PGC-1α activation by modulating LKB1, leading ) were also analyzed. All analyses were performed on BD LSR Fortessa flow cytometer (BD). Details of antibodies used are as shown in Table 2 .
Cell cycle analysis. For cell cycle analysis, BM cells were stained for stem and progenitor markers, followed by fixing using BD Cytofix/ Cytoperm. Fixed cells were then stained with KI67 and DAPI and analyzed using flow cytometry.
TKI treatment. aging, since the effects of SIRT1 deletion on normal hematopoiesis appear to differ depending on the specific models and context. The current studies focus on CML, which is an outstanding disease model that has contributed greatly to advances in leukemia pathogenesis and treatment. However, their impact extends to other hematological malignancies, including AML, myelodysplastic syndromes, and myeloproliferative neoplasms. The proposed research reveals knowledge and concepts regarding the role of SIRT1 in metabolic regulation of HSC and LSC maintenance, growth, and resistance and raises the possibility of developing improved strategies to target kinase-independent metabolic alterations.
Methods
Animal studies. ). The mice were maintained on tetracycline till CML induction. Cre activity was induced by i.p. injections of poly(I:C) (12.5 mg/kg) every other day for 7 doses. SIRT1
fl/fl mice were also crossed to ATP-linked OCR and the compensation of glycolysis for the loss of mitochondrial ATP production. FCCP uncouples the mitochondrial proton gradient and oxygen consumption from ATP synthase and drives maximal OCR. Antimycin A inhibits complex III of the electron transport chain and suppresses all mitochondrial oxygen consumption, and the residual OCR is considered nonmitochondrial. For ECAR measurements, 2-deoxy-glucose (2DG) (100 mM), a competitive inhibitor of hexokinase, was added at the end, so that basal glycolysis, maximum glycolysis, and nonglycolysis ECAR were calculated. Statistics. Results are displayed as mean ± SEM. Significance values were calculated using Prism version 5.0 software (GraphPad Prism) using unpaired, nonparametric t tests (Mann-Whitney U test) or 1-or 2-way ANOVA as appropriate. Survival was analyzed using KaplanMeier analysis. A P value of less than 0.05 was considered significant.
Study approval. All human subjects signed an informed consent form. Sample acquisition was approved by the Institutional Review Board at UAB in accordance with assurances filed with the Department of Health and Human Services and met all requirements of the Declaration of Helsinki. Mouse care and experimental procedures were performed in accordance with federal guidelines and protocols approved by the IACUC at the UAB.
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